Chairman says he declared interest
http://www.100md.com
《英国医生杂志》
The chairman of the UK joint committee on vaccination and immunisation has defended his position over the new "five in one" childhood vaccine after media reports of a potential conflict of interest over links with its makers.
Professor Michael Langman said: "Available public statements make clear that all proper procedures have been followed."
Media reports of a potential conflict of interest centre on his declaration of a non-personal interest in Merck, Sharp & Dohme, joint owners of Aventis Pasteur MSD, one of the makers of the new vaccine. (14 August, p 365)
Professor Langman, former dean of medicine at the University of Birmingham who is currently employed by the university on a part time basis, registers a non-personal interest in Merck, Sharp & Dohme, as well as in AstraZeneca and Novartis, on the joint committee's website under the heading "industrial support."
The interest in Merck, Sharp & Dohme relates to funding that goes to Birmingham University and which includes support for a clinical trial in colorectal cancer.
A Department of Health spokesman said, "Professor Langman has not received any personal benefit from Aventis Pasteur MSD since becoming chairman of JCVI . He has declared all his interests in strict accordance with the code of practice.
"The code makes clear that in such cases of non-personal interests, it is not necessary for people to stand aside from the work of the committee. The funding from this goes straight to his university and includes support for a clinical trial in colorectal cancer."(Roger Dobson)
Professor Michael Langman said: "Available public statements make clear that all proper procedures have been followed."
Media reports of a potential conflict of interest centre on his declaration of a non-personal interest in Merck, Sharp & Dohme, joint owners of Aventis Pasteur MSD, one of the makers of the new vaccine. (14 August, p 365)
Professor Langman, former dean of medicine at the University of Birmingham who is currently employed by the university on a part time basis, registers a non-personal interest in Merck, Sharp & Dohme, as well as in AstraZeneca and Novartis, on the joint committee's website under the heading "industrial support."
The interest in Merck, Sharp & Dohme relates to funding that goes to Birmingham University and which includes support for a clinical trial in colorectal cancer.
A Department of Health spokesman said, "Professor Langman has not received any personal benefit from Aventis Pasteur MSD since becoming chairman of JCVI . He has declared all his interests in strict accordance with the code of practice.
"The code makes clear that in such cases of non-personal interests, it is not necessary for people to stand aside from the work of the committee. The funding from this goes straight to his university and includes support for a clinical trial in colorectal cancer."(Roger Dobson)